Targets › BCL-XL
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.
Open in Phaseline: the race on BCL-XL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ascentage Pharma Group | APG-3288 Dual BCL-2 and MCL-1 inhibitor | BCL2, MCL1, BCL-XL | Phase 1 | Relapsed/Refractory Hematological Malignancies | Dec 2029 |
Relapsed/Refractory Hematological Malignancies (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.